Summary: The 2025 update of the ESC/EAS Guidelines for the Management of Lipid Disorders represents another step towards personalized, evidence-based prevention of cardiovascular disease. The document highlights the importance of new risk assessment models – SCORE2 and SCORE2-OP – which incorporate both cardiovascular death and non-fatal cardiovascular events and introduce non-HDL cholesterol as a primary indicator. In terms of treatment, attention is paid to the inclusion of bempedoic acid for statin-intolerant patients and evinacumab for homozygous familial hypercholesterolemia. The update also promotes early, intensive lipid management in acute coronary syndrome, based on the principle "the earlier the better." Lipoprotein (a) has been recognized as a causally significant risk factor, recommending its measurement at least once in life. Prophylactic use of statins is recommended for patients with HIV and oncology. Eicosapentaenoic acid ester and volanesorsen are considered for the treatment of hypertriglyceridemia. The guidelines recommend against the use of dietary supplements with unproven efficacy. The guidelines emphasize the central role of LDL-C lowering regardless of the method, the importance of combination therapy, and the need for individualized treatment, which is expected to lead to more effective prevention and treatment of cardiovascular disease in the European population.